Advertisement

 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links

advertisement.gif (61x7 -- 0 bytes)

   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 

 

 

Back to index

Cancer Chemotherapy Regimen for Mesothelioma Cancer


 CA                                              mesothelioma(111)
 _________________________________________________________________
  cytoxan......... 400 mg/sqm IV on days 1 and 8 or 

                   alternatively, 1,000 mg/sqm IV day 1.
  adriamycin...... 40 mg/sqm IV on days 1 and 8 or 

                   alternatively, 45 mg/sqm IV on day 1.
  FREQUENCY....... Repeat cycle every 28 days.

                   Repeat alternative cycle every 21 days.


  reference...
    Antman KH.  Pomfret EA.  Aisner J.  MacIntyre J.  Osteen RT. 
    Greenberger JS. Peritoneal mesothelioma: natural history and 
    response to chemotherapy. Journal of Clinical Oncology.  
    1(6):386-91, 1983 Jun. 
  abstract...
    Twenty-three patients with malignant peritoneal mesothelioma 
    seen at the Dana Farber Cancer Institute and the University of 
    Maryland Cancer Center from 1968 to 1982 were studied to 
    assess the natural history of the disease and the efficacy of 
    current treatment. Asbestos exposure was reported by 57%. Of 
    18 patients receiving a doxorubicin-containing regimen, 14 had 
    measurable or evaluable disease. One complete response, four 
    partial responses and one regression (in a patient with 
    evaluable but not measurable disease) were observed, ranging 
    in duration from 6 to 36 months. A single patient remains 
    disease free for more than 36 months after subsequent 
    radiotherapy. Significant clotting abnormalities (including 
    disseminated intravascular coagulation, massive thrombosis, 
    fatal pulmonary emboli, Coombs-positive hemolytic anemia, and 
    phlebitis) occurred in 22% of the patients. Trends toward 
    decreased survival were observed for smokers, patients 
    presenting with ascites, and those with stage II-IV disease. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2007 The Doctors Lounge. All rights reserved.